COVID-19 (Coronavirus)

Evaluation of M30 Apoptosense, M65 and M65 EpiDeath ELISA Assay Results

Condition: Nonalcoholic fatty liver disease (NAFLD), liver disease

Eligibility

Key Inclusion Criteria:

  • Patients suspected of nonalcoholic fatty liver disease (NAFLD)
    • At least 18 years old
    • Patients scheduled for liver biopsy due to suspicion of NASH are eligible
    • Blood must be drawn within 60 days of liver biopsy
       

Key Exclusion Criteria:

  • >21 standard drinks per week in men and >14 standard drinks per week in women
  • Etiology for other diseases
  • Steatogenic medications
     

Full Study Name

Evaluation of the Diagnostic Performance of the M30 Apoptosense, M65 and M65 EpiDeath ELISA Assay Results to Stratify Nonalcoholic Steatohepatitis (NASH) From Simple Steatosis in a Cohort of Patients Suspected of Nonalcoholic Fatty Liver Disease (NAFLD) (IRB no. PRO00056528)

Summary

This study focuses on individuals who have may have nonalcoholic fatty liver disease (NAFLD). The purpose of the study is to evaluate blood samples and tissue to discover and develop laboratory tests that can detect liver disease, as well as predict and monitor response to treatment. The study also aims to develop new blood tests for liver disease that are easily accessible to doctors and their patients. Researchers will collect medical information about participants and their specific type of liver disease to interpret results of the new blood tests.

Principal Investigator
Contact